Extended Data Fig. 8.
Lifetime number of precancer treatment events for each strategy, including different management of HPV positive women who have a negative triage, versus (A) Cervical cancer incidence ASR % reduction and (B) Cervical cancer mortality ASR % reduction. *All positive women treated after assessment of eligibility for ablative treatment. **Triage positive referred to colposcopy. ^^VIA triage positive women treated after assessment of eligibility for ablative treatment. ^HPV16/18 positive women treated after assessment of eligibility for ablative treatment; women positive for HPV types other than HPV 16/18 (‘OHR’) are triaged with VIA. +Note there could be multiple treatments in women who require follow-up.